Comparative Pharmacology
Head-to-head clinical analysis: LESSINA 21 versus ZOVIA 1 50E 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LESSINA 21 versus ZOVIA 1 50E 21.
LESSINA-21 vs ZOVIA 1/50E-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin release (FSH, LH) from pituitary, inhibiting ovulation. Causes cervical mucus thickening and endometrial alterations, impeding sperm penetration and implantation.
Combination estrogen-progestin contraceptive: Ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; Norethindrone induces cervical mucus thickening and endometrial thinning, impeding sperm penetration and implantation.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days placebo or no tablets.
One tablet orally once daily for 21 consecutive days, followed by 7 placebo tablets for 28-day cycle.
None Documented
None Documented
17-21 hours (terminal elimination half-life; clinical significance: allows once-daily dosing, but missed doses increase risk of ovulation)
Terminal elimination half-life: 13±3 hours (range 10-20 h) for the progestin component; clinical context: steady-state achieved within 5 days, with minimal accumulation.
Renal (70% as unchanged drug and metabolites), fecal (30% as metabolites)
Renal: ~50% (metabolites); Fecal: ~30% (metabolites); Biliary: minor; Unchanged drug: <1% renal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive